Skip to content
★ Sign in to follow
WB

Walvax Biotechnology Co., Ltd. Stock: price and insider trades · China

沃森生物

CN·Mcap CN¥20.6BHealth Care

No insider purchase over the last 90 days. The latest, by 广州盈沃企业管理合伙企业(有限合伙), was filed 27 Feb 2023.

Insider Decl.
13
Thresholds
n/a
Buy Volume
€14M
2 ops. · all time
Sell Volume
€62M
11 ops. · all time

Since the insiders bought

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 15,994 of 26,911 companies
45.8
score / 100
Value
27
Quality
65
FCF yld-0.1%
Earn yld0.9%
EV/EBITDA37.7x
ROE2.0%
Gross mgn75%
Net mgn7.4%
Debt/EBITDA0.7x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥12.85
Analyst consensus
1 analysts
·
CN¥7.00Target CN¥7.00(-46%)CN¥7.00
Income statement
RevenueCN¥2.4B
Gross profitCN¥1.8B75% margin
EBITDACN¥556M23% margin
Net incomeCN¥177.7M9.0% margin
Valuation
PER (trailing)116.8x
P/Book2.9x
Beta0.57
Balance sheet & cash
Market capCN¥20.6B
Total debtCN¥388.6M
Free Cash Flow-CN¥18.6M
Debt / Equity18%
Profitability & ownership
ROE2.0%
ROA1.0%
% insiders9.6%
% institutions10.1%
Last declaration on 27 February 2023
Declarations13 total
  • ▲
    董事长Executives
    25M CNY25SZSE
    667,600 shares25.3% of flowA股XSHESZSE:173000006349769820
    Canonical exit: 28 May 2023 (T+90)
  • ▲
    董事长Executives
    75M CNY29SZSE
    1,968,200 shares74.7% of flowA股XSHESZSE:173000006286409570
    Canonical exit: 18 May 2023 (T+90)
  • ▼
    高管Executives
    6M CNY37SZSE
    154,100 shares100.0% of flowA股XSHESZSE:173000006197121630
  • ▼
    高管Executives
    7M CNY36SZSE
    178,100 shares65.1% of flowA股XSHESZSE:173000006184401860
  • ▼
    高管Executives
    6M CNY37SZSE
    161,500 shares100.0% of flowA股XSHESZSE:173000006178543500
  • ▼
    高管Executives
    3M CNY32SZSE
    81,600 shares57.5% of flowA股XSHESZSE:173000006176628860
  • ▼
    高管Executives
    3M CNY32SZSE
    77,600 shares59.9% of flowA股XSHESZSE:173000006177297860
  • ▼
    高管Executives
    2M CNY30SZSE
    62,100 shares42.5% of flowA股XSHESZSE:173000006166606750
  • ▼
    高管Executives
    2M CNY30SZSE
    53,500 shares40.1% of flowA股XSHESZSE:173000006166610560
  • ▼
    高管Executives
    4M CNY14SZSE
    100,800 shares34.9% of flowA股XSHESZSE:173000006163884500
  • ▼
    董事Executives
    184M CNY12SZSE
    3,050,000 shares52.7% of flowA股XSHESZSE:173000005220698080
  • ▼
    董事Executives
    70M CNY27SZSE
    1,000,000 shares100.0% of flowA股XSHESZSE:173000004534747500
  • ▼
    董事长Executives
    177M CNY39SZSE
    2,536,747 shares47.3% of flowA股XSHESZSE:173000004455482300

13 of 13 declarations

About Walvax Biotechnology Co., Ltd.

沃森生物 (Walvax Biotechnology Co., Ltd.), a Chinese health care and pharma company valued at CNY 20.6 billion and 9.6% held by its insiders, has 13 filings published between June 2, 2021 and February 27, 2023, from 8 filers. Sales dominate in count: 11 sales worth EUR 61.6 million (median EUR 836,752) against 2 purchases worth EUR 13.7 million.

The largest sales are 李云春's: EUR 25,279,272 on January 13, 2022 as 董事, and EUR 22,707,772 on June 2, 2021 as 董事长. The same day, 黄镇 (董事) sold EUR 8,951,532. The 2 purchases, both by 广州盈沃企业管理合伙企业(有限合伙), listed as 董事长, took place in February 2023: EUR 10,264,343 on February 17 and EUR 3,471,718 on February 27.

Read moreShow less

施競, 方国良 and Wong Andrew Zilong (高管) each filed 2 times, all sales. Annual volume is 2 filings in 2021, 6 in 2022 and 5 in 2023, with a median publication delay of 0 days. No filing falls within the last twelve months.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations